Castle Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Castle Biosciences has a total shareholder equity of $455.4M and total debt of $10.0M, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are $544.7M and $89.4M respectively.
Key information
2.20%
Debt to equity ratio
US$10.04m
Debt
| Interest coverage ratio | n/a |
| Cash | US$275.93m |
| Equity | US$455.38m |
| Total liabilities | US$89.35m |
| Total assets | US$544.73m |
Recent financial health updates
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
Jun 28
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 12Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Recent updates
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
Jun 28Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
May 23When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
Apr 16Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Apr 14Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
Feb 25
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 12Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Oct 15Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Financial Position Analysis
Short Term Liabilities: CSTL's short term assets ($348.7M) exceed its short term liabilities ($50.9M).
Long Term Liabilities: CSTL's short term assets ($348.7M) exceed its long term liabilities ($38.5M).
Debt to Equity History and Analysis
Debt Level: CSTL has more cash than its total debt.
Reducing Debt: CSTL's debt to equity ratio has reduced from 15.7% to 2.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CSTL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CSTL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 9.6% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/10 21:07 |
| End of Day Share Price | 2025/08/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Castle Biosciences, Inc. is covered by 9 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |